Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system

Research output: Contribution to journalReview ArticleResearchpeer-review

62 Citations (Scopus)

Abstract

For almost 40 years since its discovery in 1953, the mineralocorticoid hormone, aldosterone, was considered to affect blood volume, and thus blood pressure, by its action to retain sodium at epithelial tissues. Over the past decade, direct effects of aldosterone on the heart and blood vessels and on the cerebral control of blood pressure have been established in experimental animals. Simultaneously, the incidence of primary aldosteronism in essential hypertension is now acknowledged to be 10-20% rather than ≤ 1%, underscoring a previously unrecognized role for aldosterone in hypertension. The 30% improvement in mortality (and 35% in morbidity) seen in the RALES trial with the addition of low-dose spironolactone to best practice therapy in moderate to severe heart failure, similarly points to an unrecognized role for aldosterone in the pathophysiology of heart failure. Currently, both experimental and clinical studies are directed towards establishing the mechanisms involved in these pathophysiological effects of aldosterone in the cardiovascular system, and of the role of mineralocorticoid receptor antagonists in offsetting or blocking such effects. A brief account of the current state of these mechanisms in at a cellular and tissue level forms the basis of this review.

Original languageEnglish
Pages (from-to)1465-1468
Number of pages4
JournalJournal of Hypertension
Volume20
Issue number8
DOIs
Publication statusPublished - Aug 2002
Externally publishedYes

Keywords

  • 11βhydroxysteroid dehydrogenase
  • Aldosterone
  • Cardiac
  • Mineralocorticoid
  • Vasculitis

Cite this

@article{9946bd5c7e7540e1b521d98e5039d53d,
title = "Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system",
abstract = "For almost 40 years since its discovery in 1953, the mineralocorticoid hormone, aldosterone, was considered to affect blood volume, and thus blood pressure, by its action to retain sodium at epithelial tissues. Over the past decade, direct effects of aldosterone on the heart and blood vessels and on the cerebral control of blood pressure have been established in experimental animals. Simultaneously, the incidence of primary aldosteronism in essential hypertension is now acknowledged to be 10-20{\%} rather than ≤ 1{\%}, underscoring a previously unrecognized role for aldosterone in hypertension. The 30{\%} improvement in mortality (and 35{\%} in morbidity) seen in the RALES trial with the addition of low-dose spironolactone to best practice therapy in moderate to severe heart failure, similarly points to an unrecognized role for aldosterone in the pathophysiology of heart failure. Currently, both experimental and clinical studies are directed towards establishing the mechanisms involved in these pathophysiological effects of aldosterone in the cardiovascular system, and of the role of mineralocorticoid receptor antagonists in offsetting or blocking such effects. A brief account of the current state of these mechanisms in at a cellular and tissue level forms the basis of this review.",
keywords = "11βhydroxysteroid dehydrogenase, Aldosterone, Cardiac, Mineralocorticoid, Vasculitis",
author = "Young, {Morag J.} and Funder, {John W.}",
year = "2002",
month = "8",
doi = "10.1097/00004872-200208000-00002",
language = "English",
volume = "20",
pages = "1465--1468",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams & Wilkins",
number = "8",

}

Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. / Young, Morag J.; Funder, John W.

In: Journal of Hypertension, Vol. 20, No. 8, 08.2002, p. 1465-1468.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system

AU - Young, Morag J.

AU - Funder, John W.

PY - 2002/8

Y1 - 2002/8

N2 - For almost 40 years since its discovery in 1953, the mineralocorticoid hormone, aldosterone, was considered to affect blood volume, and thus blood pressure, by its action to retain sodium at epithelial tissues. Over the past decade, direct effects of aldosterone on the heart and blood vessels and on the cerebral control of blood pressure have been established in experimental animals. Simultaneously, the incidence of primary aldosteronism in essential hypertension is now acknowledged to be 10-20% rather than ≤ 1%, underscoring a previously unrecognized role for aldosterone in hypertension. The 30% improvement in mortality (and 35% in morbidity) seen in the RALES trial with the addition of low-dose spironolactone to best practice therapy in moderate to severe heart failure, similarly points to an unrecognized role for aldosterone in the pathophysiology of heart failure. Currently, both experimental and clinical studies are directed towards establishing the mechanisms involved in these pathophysiological effects of aldosterone in the cardiovascular system, and of the role of mineralocorticoid receptor antagonists in offsetting or blocking such effects. A brief account of the current state of these mechanisms in at a cellular and tissue level forms the basis of this review.

AB - For almost 40 years since its discovery in 1953, the mineralocorticoid hormone, aldosterone, was considered to affect blood volume, and thus blood pressure, by its action to retain sodium at epithelial tissues. Over the past decade, direct effects of aldosterone on the heart and blood vessels and on the cerebral control of blood pressure have been established in experimental animals. Simultaneously, the incidence of primary aldosteronism in essential hypertension is now acknowledged to be 10-20% rather than ≤ 1%, underscoring a previously unrecognized role for aldosterone in hypertension. The 30% improvement in mortality (and 35% in morbidity) seen in the RALES trial with the addition of low-dose spironolactone to best practice therapy in moderate to severe heart failure, similarly points to an unrecognized role for aldosterone in the pathophysiology of heart failure. Currently, both experimental and clinical studies are directed towards establishing the mechanisms involved in these pathophysiological effects of aldosterone in the cardiovascular system, and of the role of mineralocorticoid receptor antagonists in offsetting or blocking such effects. A brief account of the current state of these mechanisms in at a cellular and tissue level forms the basis of this review.

KW - 11βhydroxysteroid dehydrogenase

KW - Aldosterone

KW - Cardiac

KW - Mineralocorticoid

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=0036668187&partnerID=8YFLogxK

U2 - 10.1097/00004872-200208000-00002

DO - 10.1097/00004872-200208000-00002

M3 - Review Article

VL - 20

SP - 1465

EP - 1468

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 8

ER -